Allegiance develops products for common diseases and conditions including Alzheimer`s, dementia, diabetes, and, inflammatory skin conditions where existing products fail to meet the needs of patients  Allegiance then obtains regulatory approvals and  patents.

Allegiance and its partners developed and patented CinGx™ and Relieva™ which will provide millions of dollars in licensing revenues.

Business Model

Allegiance has a unique model that minimize the need for in-house operations and employees. Sales and marketing costs are paid for by licensees that generate royalty revenue.

Allegiance developed a network of worldwide renowned research, regulatory organizations and universities, manufacturers, scientists and suppliers as the basis to its active portfolio of Intellectual Property (IP).These partners have given Allegiance the resources and capabilities rivaling that of some of the world’s large multinationals to develop CinGx™ and Reliéva™

This partner network of stakeholders and shareholders in Allegiance enables it to quickly take advantage of opportunities for the development of new proprietary treatments that bridge the gap where existing products fail. As such, Allegiance’s methodology leverages the use of natural ingredients to take advantage of commercialization opportunities across an array of widespread diseases. Revenues and shareholder value are generated directly by royalties and licensing fees.

Allegiance’s core competencies are product development plus effective sales and marketing strategies. All non-revenue producing activities such as manufacturing, distribution and research will be outsourced in order to minimize costs and maximize financial flexibility.